Drug survival of biologic treatments in psoriasis: a systematic review

Survival and Effectiveness of Tumour Necrosis Factor-alpha Inhibitors in the Treatment of Plaque Psoriasis under Daily Life Conditions: Report from the Psoriasis Registry Austria

(2016) M Inzinger et al.   ACTA DERMATO-VENEREOLOGICA

Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis

(2016) Peter C.M. van de Kerkhof et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Persistence and failure rates of adalimumab monotherapy in biologic-naïve patients with psoriasis: A retrospective study

(2016) Shivani P. Reddy et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): A retrospective observational study on biologic drug survival in daily practice

(2016) Eva Vilarrasa et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

(2016) A. Menter et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

(2016) Kenneth B. Gordon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treatment Patterns and Annual Drug Costs of Biologic Therapies Across Indications from the Humana Commercial Database

(2016) Andrew Howe et al.   JOURNAL OF MANAGED CARE PHARMACY

Biological therapies for psoriasis: Adherence and outcome analysis from a clinical perspective

(2015) Christopher Ross et al.   AUSTRALASIAN JOURNAL OF DERMATOLOGY

Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up

(2015) R.G. Langley et al.   BRITISH JOURNAL OF DERMATOLOGY

Long-Term Efficacy, Safety and Drug Survival of Ustekinumab in a Spanish Cohort of Patients with Moderate to Severe Plaque Psoriasis

(2015) Lluís Puig et al.   DERMATOLOGY

Comorbidity as a predictor for drug survival of biologic therapy in patients with psoriasis

(2015) Arnd Jacobi et al.   INTERNATIONAL JOURNAL OF DERMATOLOGY

Immunogenicity of Biotherapy Used in Psoriasis: The Science Behind the Scenes

(2015) Denis Jullien et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

(2015) Richard B. Warren et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Adverse events resulting in withdrawal of biologic therapy for psoriasis in real-world clinical practice: A Canadian multicenter retrospective study

(2015) Whan B. Kim et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results

(2015) Alexa B. Kimball et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis

(2015) Robert E. Kalb et al.   JAMA Dermatology

Patterns of Medication Utilization and Costs Associated with the Use of Etanercept, Adalimumab, and Ustekinumab in the Management of Moderate-to-Severe Psoriasis

(2015) Steven R. Feldman et al.   Journal of Managed Care & Specialty Pharmacy

Long-term efficacy and safety of infliximab maintenance therapy in patients with plaque-type psoriasis in real-world practice

(2014) N.H. Shear et al.   BRITISH JOURNAL OF DERMATOLOGY

‘Happy’ drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network

(2014) J.M.P.A. van den Reek et al.   BRITISH JOURNAL OF DERMATOLOGY

Drug survival is not significantly different between biologics in patients with psoriasis vulgaris: a single-centre database analysis

(2014) S.P. Menting et al.   BRITISH JOURNAL OF DERMATOLOGY

Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris

(2014) R. Gniadecki et al.   BRITISH JOURNAL OF DERMATOLOGY

What Happened after the Clinical Trials: Long-Term Safety and Efficacy of Ustekinumab in Daily Clinical Practice

(2014) Marina Talamonti et al.   DERMATOLOGY

Long-term durability and dose escalation patterns in infliximab therapy for psoriasis

(2014) Adam J. Luber et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Clinical relevance of immunogenicity of biologics in psoriasis: Implications for treatment strategies

(2014) J.-M. Carrascosa et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

(2014) Richard G. Langley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study

(2013) M. Esposito et al.   BRITISH JOURNAL OF DERMATOLOGY

Adalimumab for the treatment of psoriasis in real life: a retrospective cohort of 119 patients at a single Spanish centre

(2013) A. López-Ferrer et al.   BRITISH JOURNAL OF DERMATOLOGY

Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up

(2013) K.A. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis

(2013) K. Reich et al.   BRITISH JOURNAL OF DERMATOLOGY

Antidrug antibodies in psoriasis: a systematic review

(2013) L. Hsu et al.   BRITISH JOURNAL OF DERMATOLOGY

Biologic fatigue in psoriasis

(2013) Ethan C. Levin et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting

(2013) Machaon Bonafede et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Drug survival rates in patients with psoriasis after treatment with biologics

(2013) Yoshinori Umezawa et al.   JOURNAL OF DERMATOLOGY

OBSERVE-5 interim analysis: An observational postmarketing safety registry of etanercept for the treatment of psoriasis

(2013) Alexa B. Kimball et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Long-term study of infliximab for psoriasis in daily practice: drug survival depends on combined treatment, obesity and infusion reactions

(2013) J. Spertino et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis

(2013) Pauline A. van Schouwenburg et al.   Nature Reviews Rheumatology

A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis

(2012) A.B. Gottlieb et al.   BRITISH JOURNAL OF DERMATOLOGY

Effect of dosing frequency on chronic cardiovascular disease medication adherence

(2012) Craig I. Coleman et al.   CURRENT MEDICAL RESEARCH AND OPINION

Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis

(2012) Hidetoshi Takahashi et al.   JOURNAL OF DERMATOLOGY

Results of three analytical approaches on long-term efficacy of etanercept for psoriasis in daily practice

(2012) Paula P.M. van Lümig et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study

(2012) A.B. Kimball et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Drug survival rates of biologic treatments in patients with psoriasis vulgaris

(2011) A.M.G. Brunasso et al.   BRITISH JOURNAL OF DERMATOLOGY

Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: A phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)

(2011) Tsen-Fang Tsai et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Impact of body mass index on retention rates of anti-TNF-alfa drugs in daily practice for psoriasis

(2011) Vito Di Lernia et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial

(2011) Atsuyuki IGARASHI et al.   JOURNAL OF DERMATOLOGY

Safety of treatment with biologics for psoriasis in daily practice: 5-year data

(2011) P.P.M. van Lümig et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled study

(2010) Akihiko ASAHINA et al.   JOURNAL OF DERMATOLOGY

Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis

(2010) Christopher E.M. Griffiths et al.   NEW ENGLAND JOURNAL OF MEDICINE

Etanercept treatment patterns in managed-care patients with psoriasis or psoriatic arthritis

(2010) Sarah Thayer et al.   JOURNAL OF MEDICAL ECONOMICS

Evaluation and Management of Psoriasis: An Internist's Guide

(2009) Danielle Levine et al.   MEDICAL CLINICS OF NORTH AMERICA

Guidelines of care for the management of psoriasis and psoriatic arthritis

(2008) Alan Menter et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

(2008) Kim A Papp et al.   LANCET

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

(2007) Alan Menter et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY